PIK3CA-activating or PTEN-inactivating mutations, which are two of the most frequent genetic alterations in breast cancer [128,129], lead to abnormal PI3K pathway activation and subsequently increase phosphatidylinositol 3,4,5-triphosphate (PIP3) levels [126]. Here, PIK3CA is linked to breast carcinoma.